Lilly has now disclosed positive topline results from five Phase 3 trials and has said it intends to ask the FDA for approval in the first quarter of 2027
This signaling bias attenuates receptor desensitization, preserves receptor expression at the cell surface, and sustains prolonged therapeutic signaling
A Maintenance Plan Matters Nutrition, physical activity, follow-up care, behavioral support, and sometimes continued medication or a procedure may be needed to maintain progress
Nevertheless, until long-term human data accumulates, the precautionary approach remains appropriate
Potential Allergic Reactions: While rare, individuals taking Zepbound may experience an allergic reaction, which can present with swelling or itching around the eyes
It is not intended for type 1 diabetes or as first-line treatment in patients with a history of pancreatitis